Late-Breaking Science | Scientific Sessions

late breaking science audience and presentation

#AHA24 Late-Breaking and Featured Science announced

See the impressive lineup of science planned for presentation at Scientific Sessions 2024.

Late-breaking science| Achieving equity in prevention

Novel mechanisms for lipid-lowering therapy

LBS 08 panelists

Late-breaking science: AI at the bedside

Lbs05 Panel Web

Shocking decisions in AFib care

Lbs04 Panel2 Web

Drugs, diet and delivery can optimize hypertension outcomes

Findings evaluate dietary sodium reduction, postpartum blood pressure, an investigational RNA interference therapeutic agent and BP control and dementia risk.

audience shot

Heart failure late-breaking science

Trials highlight aspirin-free LVAD regimen, TEAMMATE and POCKET-COST-HF.

Unmet Needs in Hypertension Toolkit

Unmet Needs in Hypertension Toolkit

Learn more about initial management of HTN, diagnosing resistant hypertension, sharing decision-making with your patient and more.

A. Michael Lincoff, MD

Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes

From left: Christopher Rajkumar, MD, MRC, Jeffrey L. Carson, MD, MACP; Stefan James, MD.

Trials’ results suggest new approaches to reducing CVD risk and symptoms

Three trials provide novel approaches to reduce CVD risk.

AHA audience

Late-Breaking Science announced

See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.

audience

Early ablation bests medication in treatment naïve AFib patients

audience shot

First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension

audience shot

Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD

LBS 05 panelists

Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression

audience shot

Bivalirudin superior to unfractionated heparin in primary PCI following STEMI

Panelists of the Mindful Disruption panel

Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD

AHA speaker dais

Uncovering novel approaches in heart failure science

Aha22 Sm 2334

Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock

22 Aha Zb0087 Web

Trials’ results compare loop and thiazide diuretics and highlight ineffectiveness of novel fibrate therapy for reducing CV risk

Person putting on tennis shows

Join the Wellness Challenge at #AHA22

Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD

Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption

Lbs02 Group Blood Patel

Update on local and global hypertension science

(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA

Late-Breaking Science: New information in cardiac disease

(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA

The latest science in heart failure

(From left to right): Danielle Belardo, MD, Rafael Diaz, MD, and Christie Mitchell Ballantyne, MD, FAHA

Trials’ results highlight the potential for fish oil to fight COVID-19 and MK-0616 to lower cholesterol

(left to right): Jacqueline E. Tamis-Holland, MD, and Jane Armitage, FRCP, FFPH, OBE

New drugs, indications in cardiovascular disease